Results 1 to 10 of about 37,133 (255)

A multi-center cross-sectional investigation of BRAF V600E mutation in Ameloblastoma [PDF]

PeerJ
Background B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E mutation stands as a pivotal genetic alteration strongly associated with several neoplasms and contributes significantly to their pathogenesis as well as potential targeted treatment ...
Khin Mya Tun, Puangwan Lapthanasupkul, Anak Iamaroon, Wacharaporn Thosaporn, Poramaporn Klanrit, Sompid Kintarak, Siwaporn Thanasan, Natchalee Srimaneekarn, Nakarin Kitkumthorn   +8 more
doaj   +3 more sources

Noninvasive prediction of BRAF V600E mutation status of pleomorphic xanthoastrocytomas with MRI morphologic features and diffusion-weighted imaging [PDF]

BMC Cancer
Objectives Seeking a noninvasive predictor for BRAF V600E mutation status of pleomorphic xanthoastrocytomas (PXAs) is essential for their prognoses and therapeutic use of BRAF inhibitors.
Jing Yan, Cuiping Guo, Hongwei Zheng, Yinhua Li, Mengjiao Duan, Chaoli Zhang, Li Cui, Xiaofei Lv, Gui Fu, Jingliang Cheng   +9 more
doaj   +2 more sources

BRAF V600E Mutation in Malignant Melanoma—A Romanian Research Experience [PDF]

Medicina
Background and Objectives: The most common mutation in malignant melanoma (MM) is the single-point mutation of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) oncogene.
Elena-Roxana Avădănei, Irina-Draga Căruntu, Irina Nucă, Raluca Balan, Ludmila Lozneanu, Simona-Eliza Giusca, Cornelia Amalinei   +6 more
doaj   +2 more sources

Role of contrast-enhanced ultrasound with time-intensity curve analysis about thyroid nodule and parenchyma for differentiating BRAF V600E mutation status [PDF]

PeerJ
Background The BRAF V600E mutation was proven associated with papillary thyroid cancer (PTC) which has more aggressive behavior and could affect the outcome of PTC.
Zhipeng Hu, Rong Xue, Zhixi Liu, Liang Liu, Zheli Gong   +4 more
doaj   +3 more sources

Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma

Clinical Medicine Insights: Oncology, 2023
Background: The B-type rafkinase (BRAF) V600E gene mutation plays an important role in the pathogenesis, diagnosis, and prognosis of thyroid carcinoma. This study was conducted to investigate the rate of the BRAF V600E mutation, the relationships between
Tri Bui Dang Minh, Thuan Nghiem Duc, Van Phan Nguyen Thanh, Tuan Dinh Le, Minh Duc Tong, Trung Hoang Nguyen, Anh Le Tuan, Kien Xuan Nguyen, Tien Tran Viet, Thang Ba Ta, Son Tien Nguyen, Hai Anh Vu, Ba Van Nguyen, Dung Nguyen Thi Ngoc, Viet Tran Quoc, Thanh Bui Duc   +15 more
doaj   +1 more source

BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease. [PDF]

, 2014
Erdheim-Chester disease (ECD) is a rare histiocytosis with a high prevalence of BRAF V600E mutation (>50% of patients). Patients with BRAF-mutant ECD can respond to BRAF inhibitors.
Cabrilo, Goran, Erlander, Mark G, Hassaine, Latifa, Holley, Veronica R, Janku, Filip, Kosco, Karena, Kurzrock, Razelle, Leppin, Lorieta, Lin, Patrick P, Meric-Bernstam, Funda, Poole, Jason C, Stepanek, Vanda M, Vibat, Cecile Rose T   +12 more
core   +6 more sources

The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population

International Journal of Endocrinology, 2022
Background. The BRAF V600E mutation is an important genetic event in papillary thyroid cancer (PTC). This study aimed to provide additional information regarding the association of the BRAF V600E mutation with PTC prognosis. Methods.
Ziheng Ye, Xiaotian Xia, Peipei Xu, Wenfei Liu, Shoufei Wang, Youben Fan, Minggao Guo   +6 more
doaj   +1 more source

Predicting factors of central lymph node metastasis and BRAF V600E mutation in Chinese population with papillary thyroid carcinoma

World Journal of Surgical Oncology, 2021
Objective The aim of this study was to evaluate the predictive factors of central lymph node metastasis (CLNM) and BRAF V600E mutation in Chinese patients with papillary thyroid carcinoma (PTC).
Sheng Li Zhou, Yan Ping Guo, Lei Zhang, Tao Deng, Zi Guang Xu, Chao Ding, Wen Cong Sun, Yue Wu Zhao, Ling Fei Kong   +8 more
doaj   +1 more source

Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma. [PDF]

PLoS ONE, 2014
OBJECTIVE: To evaluate the association of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma (PTC).
Ah Young Park, Eun Ju Son, Jeong-Ah Kim, Ji Hyun Youk, Yun Joo Park, Cheong Soo Park, Hang Seok Chang   +6 more
doaj   +1 more source

BRAF V600E Immunohistochemistry Predicts Prognosis of Patients with Cutaneous Melanoma in Thai population

Plastic and Reconstructive Surgery, Global Open, 2022
Background:. The BRAF V600E mutation in the Thai population has been identified in a considerable percentage of people with cutaneous melanoma. The objectives of this study were to determine the prevalence of this mutation in cutaneous melanomas, conduct
Jiraroch Meevassana, MD, Kullawit Anothaisatapon, MD, Surawish Subbalekha, MD, Supitcha Kamolratanakul, MD, Tippawan Siritientong, RPh, PhD, Komkrit Ruangritchankul, MD, Pornthep Pungrasami, MD, Kevin J Hamill, PhD, Apichai Angsapatt, MD, Nakarin Kitkumthorn, DDS, PhD   +9 more
doaj   +1 more source